GlassScriptPhysician profile
David Russell Brear
NPI 1174548382
$1,324.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $166 · 2021: $403 · 2022: $220 · 2023: $76.25 · 2024: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $270.39 | 2019-2021 | |
| Alcon Vision LLC | $263.51 | 2019-2024 | Clareon, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $243.28 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $126.45 | 2020-2023 | Tecnis Simplicity, Veritas Vision System |
| Ocular Therapeutix, INC. | $92.75 | 2020 | |
| Eyepoint US, INC. | $82.10 | 2019 | |
| Allergan, INC. | $55.75 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $46.56 | 2022 | |
| Rxsight INC | $43.76 | 2022 | |
| Rayner Intraocular Lenses Limited | $39.94 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Oasis Medical, INC. | $27.07 | 2020-2021 | |
| Biotissue Holdings INC. | $18.23 | 2024 | |
| Eyevance Pharmaceuticals LLC | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.